Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results
Author:
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology
Link
http://www.nature.com/articles/eye200988.pdf
Reference8 articles.
1. Ghafour IM, Allan D, Foulds WS . Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983; 67: 209–213.
2. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL . Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573–1581.
3. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—VIP report no. 1. Ophthalmology 2001; 108: 841–852.
4. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA . Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368–1370.
5. Yamamoto I, Rogers HA, Reichel E, Yates P, Ducker J Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007; 91: 157–160.
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab;International Ophthalmology;2023-06-15
2. The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization;International Ophthalmology;2022-03-31
3. Baseline characteristics of myopic choroidal neovascularization in patients above 50 years old and prognostic factors after intravitreal conbercept treatment;Scientific Reports;2021-04-01
4. Choroidal Neovascularization;Pathologic Myopia;2021
5. Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye;Journal of Ophthalmology;2020-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3